Latest Safety News

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.

RemSense Technologies delivered a cashflow positive Q2 FY2025, driven by a 78% surge in customer receipts and successful execution of major global contracts. The company’s virtualplant platform continues to gain traction across mining, oil and gas, and new industrial sectors.

Opthea Limited has spotlighted Sozinibercept as a potential game-changer in wet age-related macular degeneration (AMD) therapy, presenting compelling clinical data and a clear path to U.S. market entry.

Bulletin Resources continues its appeal against the refusal of a Native Vegetation Clearing Permit critical to advancing drilling at its Ravensthorpe Lithium Project, while maintaining a strong cash position and reviewing strategic opportunities.

AuKing Mining Limited has advanced its strategic footprint with a 15% earn-in agreement at Queensland’s Cloncurry Gold Project and strengthened its board with seasoned mining experts, while navigating financial challenges and project delays.

Foresta Group Holdings has raised $3.1 million through a convertible note and share placement, while securing exclusive technology licensing and key offtake agreements to propel its flagship New Zealand biomass project.

Singular Health has secured a pivotal MoU with Miami-based Provider Network Solutions and raised $3.7 million to propel its 3Dicom software towards a US commercial pilot, supported by the appointment of esteemed radiologist Dr. Ronny Low.

Sunrise Energy Metals reports significant progress on its Syerston Scandium Project and battery materials complex, while navigating evolving global supply dynamics and maintaining a strong safety record.

Anatara Lifesciences has been granted a key Australian patent for its GaRP gastrointestinal health product, reinforcing its intellectual property portfolio ahead of pivotal clinical trial results expected in March 2025.

OncoSil Medical has achieved a key regulatory milestone with MDR certification from BSI, removing post-market restrictions and streamlining its commercial operations across Europe. This approval also paves the way for renewed efforts to enter the Australian market.

PARKD Ltd reports substantial structural completions on flagship projects and positive operating cash flow in Q2 FY25, setting the stage for licensing negotiations with Fielders.

Clarity Pharmaceuticals will present compelling data on its 64Cu-SAR-bisPSMA diagnostic agent at two leading oncology conferences, highlighting earlier and more accurate prostate cancer lesion detection than current standards.